Literature DB >> 24395183

Norisoboldine attenuates inflammatory pain via the adenosine A1 receptor.

X Gao1, Q Lu, G Chou, Z Wang, R Pan, Y Xia, H Hu, Y Dai.   

Abstract

BACKGROUND: Norisoboldine (NOR) is a benzylisoquinoline alkaloid isolated from Radix Linderae, a traditional Chinese medicine. Our previous studies have demonstrated that it produces anti-inflammatory and anti-rheumatoid arthritis effects.
METHODS: The present study was undertaken to explore the analgesic effects of NOR and its potential mechanism in the formalin test and the acetic acid writhing test.
RESULTS: Oral administration of NOR dose dependently attenuated the formalin-induced pain responses in the second phase, and reduced formalin-induced paw oedema. It also diminished acetic acid-induced writhing responses but had no effect on acute thermal pain in the hotplate test. The mechanistic studies suggested that the adenosine system, but not the opioid receptor system, is involved in NOR-induced antinociception. Naloxone, a non-selective opioid receptor antagonist, had no effect on NOR-induced analgesic action. However, caffeine (a non-selective adenosine receptor antagonist) completely reversed the analgesic effect of NOR in formalin-induced nociceptive responses in the second phase, and 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX, a selective adenosine A1 receptor antagonist) completely inhibited NOR-induced analgesia in both formalin-induced nociceptive responses and acetic acid-induced writhing responses. In addition, NOR reduced formalin-induced activation of extracellular signal-regulated kinase and calcium/calmodulin-dependent protein kinase II in the spinal cord, which is also blocked by DPCPX. Furthermore, NOR decreased forskolin-evoked cyclic adenosine monophosphate levels in mouse spinal cord neuronal cultures through the adenosine A1 receptor.
CONCLUSION: Our data demonstrate that NOR produces the analgesic effect in inflammatory pain by a mechanism related to the adenosine system.
© 2014 European Pain Federation - EFIC®

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395183     DOI: 10.1002/j.1532-2149.2013.00439.x

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  7 in total

1.  Antinociceptive, antiedematous, and antiallodynic activity of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives in experimental models of pain.

Authors:  Anna Dziubina; Dominika Szkatuła; Joanna Gdula-Argasińska; Magdalena Kotańska; Barbara Filipek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-12-19       Impact factor: 3.000

2.  Paeoniflorin exerts analgesic and hypnotic effects via adenosine A1 receptors in a mouse neuropathic pain model.

Authors:  Dou Yin; Yuan-Yuan Liu; Tian-Xiao Wang; Zhen-Zhen Hu; Wei-Min Qu; Jiang-Fan Chen; Neng-Neng Cheng; Zhi-Li Huang
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

Review 3.  A1 Adenosine Receptor Activation Modulates Central Nervous System Development and Repair.

Authors:  Shirin Kashfi; Kamran Ghaedi; Hossein Baharvand; Mohammad Hossein Nasr-Esfahani; Mohammad Javan
Journal:  Mol Neurobiol       Date:  2016-11-26       Impact factor: 5.590

4.  A1 Adenosine Receptor Activation Inhibits P2X3 Receptor-Mediated ATP Currents in Rat Dorsal Root Ganglion Neurons.

Authors:  Jia-Wei Hao; Wen-Long Qiao; Qing Li; Shuang Wei; Xue-Mei Li; Ting-Ting Liu; Chun-Yu Qiu; Wang-Ping Hu
Journal:  Mol Neurobiol       Date:  2022-09-08       Impact factor: 5.682

Review 5.  Molecular Targets of Cannabidiol in Neurological Disorders.

Authors:  Clementino Ibeas Bih; Tong Chen; Alistair V W Nunn; Michaël Bazelot; Mark Dallas; Benjamin J Whalley
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 6.  The purinergic system and glial cells: emerging costars in nociception.

Authors:  Giulia Magni; Stefania Ceruti
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

Review 7.  Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain.

Authors:  Fabrizio Vincenzi; Silvia Pasquini; Pier Andrea Borea; Katia Varani
Journal:  Int J Mol Sci       Date:  2020-11-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.